<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2938">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374474</url>
  </required_header>
  <id_info>
    <org_study_id>Anosmia_CoVID 19</org_study_id>
    <nct_id>NCT04374474</nct_id>
  </id_info>
  <brief_title>Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)</brief_title>
  <official_title>Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a randomized controlled trial, involving patients with hyposmia/anosmia of
      onset immediately after an upper respiratory viral illness, assigned to three distinct study
      arms. Nasal irrigations will be prescribed to all three groups (BID). In addition, one arm
      will receive a paper hand-out about post-viral anosmia with instructions to smell common
      household items (current care) and act as a control group. The second group will receive an
      essential oil retraining kit, whereas the third group will receive the same olfactory
      training kit and a prescription to use budesonide with the nasal irrigations. Olfactory
      scores will be tested at the enrollment, 3 months and at 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study withdrawn before any enrollment (site's research goals adjustments).
  </why_stopped>
  <start_date type="Anticipated">January 10, 2021</start_date>
  <completion_date type="Anticipated">March 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Snap and Sniff Threshold Test at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Score from the Snap and Sniff Olfactory Test results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Smell Identification Test (SIT) at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Score from the Smell Identification test results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Snap and Sniff Threshold Test at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Score from the Snap and Sniff Olfactory Test results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Smell Identification Test (SIT) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Score from the Smell Identification test results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline QOD-NS at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline SF-36 health survey at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Short Form 36 Health Survey scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline QOD-NS at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline SF-36 health survey at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Short Form 36 Health Survey scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to the Study Protocol</measure>
    <time_frame>6 months</time_frame>
    <description>Adherence comparison between participants post-CoVID 19 and patients post other viral infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery</measure>
    <time_frame>6 months</time_frame>
    <description>Compare the rate of recovery between post-COVID 19 patients and patients post other viral infections.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Olfactory Disorder</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The participants, randomly assigned to this arm, will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care). Besides, it will be prescribed nasal irrigation twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olfactory Retraining Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants, randomly assigned to this arm, will receive instructions on olfactory retraining and will also be given an essential oil retraining kit, which they will use twice a day. Besides, it will be prescribed nasal irrigation twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olfactory Retraining_Budesonide Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants, randomly assigned to this arm, will receive instructions on olfactory retraining, the olfactory training kit and it will be prescribed nasal irrigation with Budesonise, twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olfactory retraining</intervention_name>
    <description>Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.</description>
    <arm_group_label>Olfactory Retraining Group</arm_group_label>
    <arm_group_label>Olfactory Retraining_Budesonide Group</arm_group_label>
    <other_name>essential oils kit</other_name>
    <other_name>smell training</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroid nasal irrigation</intervention_name>
    <description>Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).</description>
    <arm_group_label>Olfactory Retraining_Budesonide Group</arm_group_label>
    <other_name>Budesonide nasal irrigation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>smell household Items</intervention_name>
    <description>Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal Irrigation</intervention_name>
    <description>Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Olfactory Retraining Group</arm_group_label>
    <other_name>Nasal Rinse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years of age or older

          -  Hyposmia/anosmia of onset immediately after an upper respiratory viral illness
             confirmed on Snap n' Sniff threshold testing,

          -  Capable, in the opinion of the primary investigator, of providing informed consent to
             participate in the study. Participants are required to sign an informed consent form
             indicating they understand the purpose and nature of the study, and that they are
             willing to participate.

        Exclusion Criteria:

          -  active cigarette smoker

          -  chronic rhinosinusitis

          -  head trauma with loss of consciousness

          -  inability to read/understand English

          -  previous hyposmia/anosmia complaint

          -  pregnancy

          -  previous sinus

          -  skull base or brain surgery

          -  current participation in another clinical trial at the time of initial visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leigh Sowerby, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Vennemann MM, Hummel T, Berger K. The association between smoking and smell and taste impairment in the general population. J Neurol. 2008 Aug;255(8):1121-6. doi: 10.1007/s00415-008-0807-9. Epub 2008 Jul 28.</citation>
    <PMID>18677645</PMID>
  </reference>
  <reference>
    <citation>Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life--an updated review. Chem Senses. 2014 Mar;39(3):185-94. doi: 10.1093/chemse/bjt072. Epub 2014 Jan 15. Review.</citation>
    <PMID>24429163</PMID>
  </reference>
  <reference>
    <citation>Konstantinidis I, Tsakiropoulou E, Bekiaridou P, Kazantzidou C, Constantinidis J. Use of olfactory training in post-traumatic and postinfectious olfactory dysfunction. Laryngoscope. 2013 Dec;123(12):E85-90. doi: 10.1002/lary.24390. Epub 2013 Oct 4.</citation>
    <PMID>24114690</PMID>
  </reference>
  <reference>
    <citation>Nguyen TP, Patel ZM. Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss. Int Forum Allergy Rhinol. 2018 Sep;8(9):977-981. doi: 10.1002/alr.22140. Epub 2018 Jun 14.</citation>
    <PMID>29901865</PMID>
  </reference>
  <reference>
    <citation>Mattos JL, Edwards C, Schlosser RJ, Hyer M, Mace JC, Smith TL, Soler ZM. A brief version of the questionnaire of olfactory disorders in patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019 Oct;9(10):1144-1150. doi: 10.1002/alr.22392. Epub 2019 Aug 20.</citation>
    <PMID>31430061</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anosmia</keyword>
  <keyword>hyposmia</keyword>
  <keyword>CoVID19</keyword>
  <keyword>post-viral anosmia</keyword>
  <keyword>snap and sniff olfactory test</keyword>
  <keyword>budesonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olfaction Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

